Acute myeloid leukaemia vaccine - GSK

Drug Profile

Acute myeloid leukaemia vaccine - GSK

Alternative Names: 2130579A; GSK 2130579A; WT1-A10+AS01B ASCI

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Corixa Corp
  • Developer GlaxoSmithKline
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia

Most Recent Events

  • 01 Jun 2016 GlaxoSmithKline completes a phase I trial for Acute myeloid leukaemia in USA and France (NCT00725283)
  • 01 Apr 2016 GlaxoSmithKline completes a phase I trial in Acute myeloid leukaemia in USA, France and Germany (IM) (NCT01051063)
  • 20 Apr 2012 GlaxoSmithKline completes enrolment in its phase I trial for Acute myeloid leukaemia in USA and France (NCT00725283)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top